| Literature DB >> 9663595 |
T M Wagner1, R A Möslinger, D Muhr, G Langbauer, K Hirtenlehner, H Concin, W Doeller, A Haid, A H Lang, P Mayer, E Ropp, E Kubista, B Amirimani, T Helbich, A Becherer, O Scheiner, H Breiteneder, A Borg, P Devilee, P Oefner, C Zielinski.
Abstract
We identified 17 BRCA1 mutations in 86 Austrian breast and ovarian cancer families (20%) that were screened for mutations by denaturing high-performance liquid chromatography (DHPLC) and the protein truncation test (PTT). Eleven distinct mutations were detected, 4 of them (962del4, 2795del4, 3135del4 and L3376stop) not previously reported in families of non-Austrian origin. In addition, 6 rare missense mutations (allele frequency < 1%) with unknown biological effects were identified. Four mutations occurred more than once in the Austrian population: 2795del4 (3 times), Cys61Gly (3 times) 5382insC (2 times) and Q1806stop (2 times). Haplotype analysis of the 4 recurrent mutations suggested a common ancestor for each of these. Thirty-four breast cancer cases from 17 families with BRCA1 mutations were further analyzed. We observed a low median age of onset (39.5 years). Sixty-eight percent of all BRCA1 breast cancer cases had negative axillary lymph nodes. This group showed a significant prevalence of a negative estrogen and progesterone receptor status and stage I tumors compared with an age-related, node-negative control group. The prevalence of grade III tumors was marginally significant. Survival analysis either with a control group matched for age (within 5 years), grade, histologic subtype and estrogen receptor status, or with an age-related, node-negative comparison group, showed no statistical difference.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9663595 DOI: 10.1002/(sici)1097-0215(19980729)77:3<354::aid-ijc8>3.0.co;2-n
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396